Akunah Pty, Ltd.

Akunah Pty, Ltd. specializes in developing orthopaedic and craniofacial implantation planning software. These tools are designed to assist surgeons in visualizing and planning implant placements preoperatively, improving precision and surgical outcomes. The focus is on software-based solutions rather than physical devices.

Akunah Pty, Ltd. is based in the United States, which means its devices fall under FDA jurisdiction. Since the company’s products are classified as Class II medical devices, they are subject to FDA regulations like the 510(k) premarket notification process and UDI (Unique Device Identification) requirements. The U.S. location also influences compliance pathways, such as mandatory registration and reporting obligations.

Akunah’s devices are listed in the FDA 510(k) and FDA UDI registries. The 510(k) registry tracks devices that have undergone premarket notification to demonstrate substantial equivalence to a predicate device, ensuring they meet safety and effectiveness standards. The UDI system assigns unique identifiers to devices to improve tracking, traceability, and post-market surveillance—critical for patient safety and regulatory compliance.

Akunah’s devices are classified as Class II by the FDA. This classification indicates they pose moderate risk and require special controls beyond general controls (like good manufacturing practices) to ensure safety and performance. While Class II devices don’t require clinical trials like Class III, they still undergo rigorous review through the 510(k) process to confirm they meet regulatory requirements before commercialization.

Akunah’s products are software-based medical devices, specifically orthopaedic/craniofacial implantation planning tools. Unlike physical devices, software devices are regulated based on their intended use and risk level. In this case, the software’s role in preoperative planning—where errors could impact patient safety—classifies it as a Class II device, subjecting it to FDA oversight to validate its performance, validation methods, and cybersecurity considerations where applicable.